• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Chal

tetano

Editor, Senior Moderator
Front Immunol. 2018 Oct 12;9:2350. doi: 10.3389/fimmu.2018.02350. eCollection 2018.
[h=1]Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.[/h] van der Lubbe JEM[SUP]1[/SUP], Verspuij JWA[SUP]1[/SUP], Huizingh J[SUP]1[/SUP], Schmit-Tillemans SPR[SUP]1[/SUP], Tolboom JTBM[SUP]1[/SUP], Dekking LEHA[SUP]1[/SUP], Kwaks T[SUP]1[/SUP], Brandenburg B[SUP]1[/SUP], Meijberg W[SUP]1[/SUP], Zahn RC[SUP]1[/SUP], Roozendaal R[SUP]1[/SUP], Kuipers H[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Seasonal influenza vaccines are updated almost annually to match the antigenic drift in influenza hemagglutinin (HA) surface glycoprotein. A new HA stem-based antigen, the so-called "mini-HA," was recently shown to induce cross-protective antibodies. However, cross-reactive antibodies targeting the HA stem can also be found in mice and humans after administration of seasonal vaccine. This has raised the question whether in similar conditions such a mini-HA would be able to show an increased breadth of protection over immunization with full length (FL) HA. We show in mice that in a direct comparison to H1 FL HA, using the same immunization regimen, dosing and adjuvant, a group 1 mini-HA has a higher protective efficacy against group 1 influenza virus challenges not homologous to the H1 FL HA. Although both antigens induce a similar breadth of HA subtype binding, mini-HA immunization induces significantly more HA stem-specific antibodies correlating with survival. In addition, both mini-HA and H1 FL HA immunization induce influenza neutralizing antibodies while mini-HA induces significantly higher levels of mFcγRIII activation, involved in Fc-mediated antibody effector functions. In agreement with previous findings, this confirms that more than one mechanism contributes to protection against influenza. Together our results further warrant the development of a universal influenza vaccine based on the HA stem region.


[h=4]KEYWORDS:[/h] antibodies; hemagglutinin stem immunogen; influenza; mouse influenza challenge models; universal influenza vaccine

PMID: 30369928 PMCID: PMC6194913 DOI: 10.3389/fimmu.2018.02350
Free full text
 
Back
Top Bottom